⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15571217 | 0.75 | — | — | |
| SCHEMBL8060100 | 0.74 | — | — | |
| SCHEMBL10600268 | 0.74 | — | — | |
| SCHEMBL10600274 | 0.74 | — | — | |
| SCHEMBL11272928 | 0.70 | — | — | |
| SCHEMBL11272925 | 0.70 | — | — | |
| SCHEMBL3119562 | 0.70 | PPARG (0.42) | — | |
| SCHEMBL7481435 | 0.69 | — | — | |
| SCHEMBL7481441 | 0.69 | — | — | |
| SCHEMBL3307734 | 0.68 | PPARG (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716554-A1 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | Allygen Group (KY) | 2026-04-01 | — | — | EP | disclosed |
| EP-4661902-A1 | COMPOSITIONS INCLUDING ANTI-WT-1 ANTIBODIES & ANTIGEN BINDING FRAGMENTS AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12479924-B2 | Constructs specifically recognizing Glypican 3 and uses thereof | Eureka Therapeutics, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250199010-A1 | BINDER MOLECULES WITH HIGH AFFINITY AND/ OR SPECIFICITY AND METHODS OF MAKING AND USE THEREOF | ALAMAR BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250170265-A1 | DIAZONIUM COMPOUNDS AND METHODS OF USE FOR DNA CLEAVAGE | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025096433-A1 | CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024240162-A9 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2025-04-10 | — | — | WO | disclosed |
| US-20250011463-A1 | CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | Eureka Therapeutics, Inc. | 2025-01-09 | — | — | US | disclosed |
| WO-2024240162-A1 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2024-11-28 | — | — | WO | disclosed |
| CN-112888709-B | Constructs for targeting CD22 and uses thereof | 优瑞科生物技术公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20220323497-A1 | CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF | EUREKA THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11447564-B2 | Constructs specifically recognizing glypican 3 and uses thereof | Eureka Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220265715-A1 | CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF | EUREKA THERAPEUTICS INC (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022147463-A2 | BINDER MOLECULES WITH HIGH AFFINITY AND/ OR SPECIFICITY AND METHODS OF MAKING AND USE THEREOF | ALAMAR BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220185910-A1 | CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | Eureka Therapeutics, Inc. | 2022-06-16 | — | — | US | disclosed |
| US-11355782-B2 | Electrolytic solution for secondary batteries, secondary battery, battery pack, electric vehicle, electric power storage system, electric power tool, and electronic device | MURATA MANUFACTURING CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-4003373-A1 | CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4004030-A1 | CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022026759-A1 | T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF | Eureka Therapeutics, Inc. (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-0570594-B1 | HYDROXAMIC ACID DERIVATIVE BASED ON AROMATIC SULFONAMIDE | SHIONOGI & CO (JP) | 1997-07-30 | — | — | EP | disclosed |